Bridgeway Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

Bridgeway Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.46M	Buy	791,434 +67,957	+9%	+$166K	0.03%	646
2026 Q1	$1.54M	Buy	723,477 +550,177	+317%	+$1.31M	0.03%	597
2025 Q4	$421K	Buy	173,300 +75,000	+76%	+$266K	0.01%	857
2025 Q3	$373K	Hold	98,300	–	–	0.01%	865
2025 Q2	$244K	Buy	98,300 +25,200	+34%	+$48.6K	0.01%	920
2025 Q1	$113K	Sell	73,100 -71,500	-49%	-$150K	﹤0.01%	1015
2024 Q4	$309K	Sell	144,600 -4,600	-3%	-$13.2K	0.01%	916
2024 Q3	$649K	Sell	149,200 -23,800	-14%	-$130K	0.01%	800
2024 Q2	$806K	Hold	173,000	–	–	0.02%	745
2024 Q1	$877K	Sell	173,000 -19,000	-10%	-$76.6K	0.02%	776
2023 Q4	$540K	Buy	192,000 +65,500	+52%	+$154K	0.01%	921
2023 Q3	$363K	Buy	126,500 +51,500	+69%	+$190K	0.01%	969
2023 Q2	$379K	Hold	75,000	–	–	0.01%	981
2023 Q1	$142K	Sell	75,000 -50,000	-40%	-$115K	﹤0.01%	1169
2022 Q4	$225K	Hold	125,000	–	–	0.01%	1062
2022 Q3	$211K	Buy	125,000 +59,800	+92%	+$184K	0.01%	1130
2022 Q2	$160K	Sell	65,200 -12,000	-16%	-$27.9K	﹤0.01%	1137
2022 Q1	$214K	Buy	+77,200	New	+$282K	﹤0.01%	1160

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Bridgeway Capital Management's BDTX Position: Q2 2026 in Review

Bridgeway Capital Management increased its Black Diamond Therapeutics (BDTX) stake by 9.4% in Q2 2026, buying an estimated $166K and bringing the position to 791,434 shares worth $1.46M. The position accounts for 0.03% of the portfolio, ranked #646.

Bridgeway Capital Management first reported a position in BDTX in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.54M in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

Bridgeway Capital Management held 791,434 shares of Black Diamond Therapeutics worth $1.46M as of Q2 2026.
Bridgeway Capital Management bought 67,957 Black Diamond Therapeutics shares in Q2 2026, an estimated $166K.
Black Diamond Therapeutics made up 0.03% of Bridgeway Capital Management's portfolio in Q2 2026, its #646 holding.
Bridgeway Capital Management first reported a position in Black Diamond Therapeutics in Q1 2022 and has held it in 18 quarters since.
Bridgeway Capital Management's Black Diamond Therapeutics position peaked at $1.54M in Q1 2026.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.